Ivy-Joan Madu is an Endocrinology/Metabolic physician. OpenAlex indexes 6 publications with 904 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1310 W Stewart Dr Ste 610
Orange, CA 928683857
Telephone
714-639-1815Provider last certified this registry record 16 Apr 2022.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202514 payments
- ABBVIE INC.Program year20254 payments
- Novo Nordisk IncProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.9%Insulin Analog21.3%Lantus Solostar28%Humalog Kwikpen U-10016%Tresiba Flextouch U-10011%Toujeo Solostar7%Toujeo Max Solostar5%Novolog Flexpen5%Humalog5%Insulin Lispro Kwikpen U-1005%Basaglar Kwikpen U-1004%Lantus3%Fiasp Flextouch3%Insulin Glargine-Yfgn2%Tresiba Flextouch U-2002%Novolog2%Levemir Flexpen1%Lyumjev Kwikpen U-1001%Part D<11 patientsGLP-1 receptor agonist16.7%Ozempic65%Mounjaro20%Trulicity12%Rybelsus2%Wegovy1%Part D<11 patients+ 14 more classes in this area
Hormonal (systemic)
19%l-Thyroxine15.2%Levothyroxine Sodium86%Synthroid14%Part D≥197 patientsThyroid Hormone Synthesis Inhibitor1.6%Methimazole82%Propylthiouracil18%Part D<11 patients+ 4 more classes in this area
Cardiovascular
14.9%Statin7%Atorvastatin Calcium44%Rosuvastatin Calcium30%Simvastatin19%Pravastatin Sodium4%Lovastatin4%Part D<11 patientsCalcium channel blocker1.8%Amlodipine Besylate100%Part D≥34 patients+ 9 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
The Journal of Clinical Endocrinology & Metabolism
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”